Neil K. Warma, President & CEO, Opexa Therapeutics, delves into Opexa’s Phase 2B ABILI-T Clinical Trial for secondary progressive multiple sclerosis (MS) that expects to yield top-line results in 2016. Previous studies showed that with a similar patient population, the drug prevented disease progression in 80% of secondary progressive MS patients.

Resources & References:

http://www.clinicaltrials.gov/ct2/show/NCT01684761?term=opexa&rank=3

http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS

http://www.opexatherapeutics.com/